LifeMD, Inc.
NASDAQ•LFMD
CEO: Mr. Justin Schreiber
Sector: Healthcare
Industry: Medical - Pharmaceuticals
Listing Date: 2008-01-29
LifeMD, Inc. operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies. It also provides LifeMD PC, a direct-to-consumer virtual primary care which includes 24/7 access to a provider for their primary care, urgent care, and chronic care needs; and offers virtual consultations and treatment, prescription medications, diagnostics and imaging, wellness coaching, and more. In addition, the company offers PDFSimpli, an online software as a service platform that allows users to create, edit, convert, sign, and share PDF documents; ResumeBuild which provides digital resume and cover letter services; SignSimpli, a digital signature platform; and LegalSimpli, a provider of legal forms for consumers and small businesses. It sells its products directly to consumers and through e-commerce platforms, as well as through third party partner channels. The company was formerly known as Conversion Labs, Inc. and changed its name to LifeMD, Inc. in February 2021. LifeMD, Inc. was incorporated in 1994 and is headquartered in New York, New York.
Contact Information
Market Cap
$213.72M
P/E (TTM)
14.3
102
Dividend Yield
--
52W High
$15.84
52W Low
$2.56
52W Range
Rank64Top 94.9%
1.7
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 1.7 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025
Financial Dashboard
Q4 2025 Data
Revenue
$5.97M+0.00%
4-Quarter Trend
EPS
-$0.05+0.00%
4-Quarter Trend
FCF
-$3.44M+0.00%
4-Quarter Trend
2025 Annual Earnings Highlights
Key Highlights
Telehealth Revenue Increased 25% Net telehealth revenue reached $194.06M in 2025, driven by strong online sales demand and subscription growth.
Continuing Operations Loss Reduced Net loss from continuing operations narrowed to $(10.23M) in 2025, significantly improving from $(23.18M) loss in 2024.
Strategic Transformation Milestone Achieved Completed WorkSimpli divestiture and acquired OHHMD, focusing exclusively on virtual care and pharmacy expansion.
Working Capital Position Strengthened Working capital improved by $25.3M to a positive $10.26M balance at year-end 2025, up from deficit.
Risk Factors
Continued Operating Losses Expected Expect costs to increase in foreseeable future; profitability remains uncertain despite revenue growth and operational focus.
Regulatory Compliance Complexity High Subject to evolving state/federal laws regarding telehealth, data privacy (HIPAA, MHMDA), and potential fee-splitting claims.
Material Internal Control Weaknesses Identified material weaknesses in revenue recording, segregation of duties, and IT general controls requiring substantial remediation efforts.
Platform Dependency Risks Exist Service continuity relies heavily on third-party providers like AWS and partner pharmacies; interruptions could cause material harm.
Outlook
Insurance Coverage Expansion Planned Expect network coverage to expand to 230 million lives by June 2026, covering 80% of US commercially insured lives.
AI Integration Enhances Efficiency Leveraging AI/LLMs to improve clinical operations, product development, and overall agility; mitigating associated ethical risks required.
Focus on GLP-1 Access Enhancing access to branded GLP-1 medications via electronic benefits verification and direct manufacturer integrations planned.
Remediation Plan Execution Ongoing Management is executing a plan to remediate material weaknesses throughout 2026, focusing on revenue reporting and IT controls.
Peer Comparison
Revenue (TTM)
$2.76B
$424.09M
$349.88M
Gross Margin (Latest Quarter)
93.9%
92.9%
87.3%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| CERS | $345.91M | -22.0 | -26.4% | 43.7% |
| ACIU | $333.99M | -3.6 | -101.6% | 2.9% |
| RXST | $311.97M | -7.9 | -14.0% | 3.5% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
-55.0%
Growth Under Pressure
4Q Net Income CAGR
138.8%
Profitability Improved
Cash Flow Stability
50%
Cash Flow Needs Attention
Deep Research
Next earnings:May 4, 2026
EPS:-
|Revenue:-
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement | LTM |
|---|
No Data